Anoat Therapeutics, a Paris, France-based preclinical stage biotechnology company specialized in Cystic Fibrosis (CF), raised €2M in Seed funding.
The round was led by AdBio partners, a venture capital company specialized in seed investments in life sciences startups.
The company intends to use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate.
Led by CEO Vincent Bischoff, Anoat Therapeutics is a preclinical-stage company focused on developing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its team leverages its proven track record in rare diseases and AntiSens Oligonucleotide (ASO) drug development to build a pipeline of novel drug candidates.
Anoat’s lead program is an ASO designed to target an alternative chloride channel and compensate for the defective/lacking activity of the CFTR (Cystic Fibrosis Transmembrane conductance Regulator) channel protein in Cystic Fibrosis (CF) patients.
The company leverages academic work generated by Pr. Harriet Corvol, MD, PhD, Dr. Olivier Tabary, PhD, Dr. Christie Mitri, PhD, and Dr. Florence Sonneville, PhD, from Inserm.
FinSMEs
19/06/2023